ACRS News and Press, Aclaris Therapeutics Inc. From 10/08/19

WAYNE, Pa., Oct. 08, 2019 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (Nasdaq: ACRS), a physician-led biopharmaceutical company focused on immuno-inflammatory diseases, announced today that the company, together with Allergan, Inc., has filed a patent infringement lawsuit in the United S...

New York, New York--(Newsfile Corp. - September 25, 2019) - Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Aclaris Therapeutics, Inc. (NASDAQ: ACRS) ("Aclaris" or the "Company") of the September 30, 2019 deadline to seek the role of lead plaintiff in a f...

Aclaris Therapeutics ( ACRS ) announced that it had obtained positive results in a Phase 3 study using A-101 45% topical solution to treat patients with common warts (also known as verruca vulgaris). With this being the first of two Phase 3 studies, there is another late-stage trial read...

Gainers: Interlink Electronics ( OTCPK:LINK ) +37% . Avadel Pharmaceuticals plc (NASDAQ: AVDL ) +33% . Arotech Corporation (NASDAQ: ARTX ) +31% . Plus Therapeutics (NASDAQ: PSTV ) +25% . Cesca Therapeutics (NASDAQ: KOOL ) +20% . PriceSmart (NASDAQ: PSMT ) +18% . Dova Pharmaceuticals...

The NASDAQ Biotechnology Index (INDEXNASDAQ: NBI ) rose last week from 3,267.22 points on Monday’s (September 16) open to 3,319.26 points as of 12:37 p.m. EDT on Friday (September 20). On Monday, Alder BioPharmaceuticals (NASDAQ: ALDR ) announced that it is going to be acquired by D...

With one product candidate at Phase 3 of development and expecting completion in early 2020, Aclaris Therapeutics ( ACRS ) is a name to be followed carefully. The Phase 3 trial is estimated to be completed on January 15, 2020. With that said, the company’s cash burn rate is very signifi...

Gainers:  Aclaris Therapeutics (NASDAQ: ACRS ) +68% . Avadel Pharmaceuticals plc (NASDAQ: AVDL ) +20% . BioCardia ( OTCQB:BCDA ) +15% . Lexicon Pharmaceuticals (NASDAQ: LXRX ) +14% . Earthstone Energy (NYSE: ESTE ) +14% . Pier 1 Imports (NYSE: PIR ) +15% . SunPower Corporation (...

Aclaris Therapeutics (NASDAQ: ACRS ) +73%  on positive A-101 data . More news on: Aclaris Therapeutics, Inc., Capricor Therapeutics, Inc., Ocean Power Technologies, Inc., Stocks on the move, Read more ...

WAYNE, Pa., Sept. 17, 2019 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a physician-led biopharmaceutical company focused on immuno-inflammatory diseases, today announced it will host an R&D day for analysts and investors focused on its pipeline of novel drug candidate...

A Phase 3 clinical trial, THWART-2 , evaluating Aclaris Therapeutics' (NASDAQ: ACRS ) A-101 45% topical solution for the treatment of common warts met the primary endpoint of a statistically significant proportion of patients whose identified warts were clear at day 60 compared to vehicle (...